Genix Pharmaceuticals (TSXV:GENX) Debt-to-Equity : -0.48 (As of Jan. 2024)

View and export this data going back to 1999. Start your Free Trial

What is Genix Pharmaceuticals Debt-to-Equity?

Genix Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$0.58 Mil. Genix Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$0.00 Mil. Genix Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Jan. 2024 was C$-1.20 Mil. Genix Pharmaceuticals's debt to equity for the quarter that ended in Jan. 2024 was -0.48.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Genix Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

TSXV:GENX' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.51 Med: 0.01 Max: 0.16
Current: -0.48

During the past 13 years, the highest Debt-to-Equity Ratio of Genix Pharmaceuticals was 0.16. The lowest was -0.51. And the median was 0.01.

TSXV:GENX's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.29 vs TSXV:GENX: -0.48

Genix Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Genix Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genix Pharmaceuticals Debt-to-Equity Chart

Genix Pharmaceuticals Annual Data

Trend

Oct14

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Debt-to-Equity

Get a 7-Day Free Trial

-0.50

0.01

0.06

-0.45

Genix Pharmaceuticals Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Debt-to-Equity	Get a 7-Day Free Trial															0.11	0.14	0.16	-0.45	-0.48

Competitive Comparison of Genix Pharmaceuticals's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Genix Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genix Pharmaceuticals's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genix Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Genix Pharmaceuticals's Debt-to-Equity falls into.

Genix Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Genix Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Oct. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.512	+	0)	/	-1.137
	=	-0.45

Genix Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Jan. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.575	+	0)	/	-1.196
	=	-0.48

Genix Pharmaceuticals (TSXV:GENX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Genix Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Genix Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Genix Pharmaceuticals (TSXV:GENX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Genix Pharmaceuticals Corp (TSXV:GENX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

GENPF:USA

Address

1055 West Hastings Street, Suite 300, Vancouver, BC, CAN, V6E 1J8

Website

https://www.genixpharm.com

Genix Pharmaceuticals Corp is a Canadian life sciences company. It operates as a formulator, manufacturer, licensor, and marketer of life sciences related products with a focus on nutraceuticals and pharmaceuticals. Some of its products are Renochlor, Sucanon, and Flu-X. The company primarily operates in Canada.

Executives

Sina Pirooz

Director

Genix Pharmaceuticals (TSXV:GENX) Headlines

No Headlines